Publications
Links to our latest financial and sustainability reports and other recent publications.
Innovation
CHRONOS-PD: Plasma Science in Parkinson’s Research
Seeking early biological signs of disease.
Showing 218 search results
Press release
Grifols completes enrollment of second cohort in first-in-human Alpha-1 15% subcutaneous option for treating alpha1-antitrypsin deficiency
Press release
Grifols collaborates with startup FcR Therapeutics to develop recombinant therapies for autoimmune diseases
Press release
Grifols pioneers high-tech analysis of plasma bank to detect early signs of Parkinson’s disease
Press release
Grifols submits Biologics License Application for its new fibrinogen solution to U.S. FDA
Press release
Grifols announces topline phase 3 data on long-term Albutein® (albumin [human] U.S.P.) therapy for decompensated cirrhosis with ascites
Press release
Grifols ranked number one biotech company in Dow Jones Sustainability Indices
Financial Report
Explore our last financial and earnings report.
Sustainability Report
Integrated and Sustainability Annual Report.
Position Paper
The differential value of plasma-derived medicinal products (PDMPs).
Press Kit
Explore our Press Kit to find key facts and figures on Grifols.
Media Contacts
If you're a journalist or media professional with a question, contact our media relations team.